Literature DB >> 2750591

Structural features of some diphenhydramine analogues that determine the interaction with rat liver cytochrome P-450.

E Rekka1, H Timmermann, A Bast.   

Abstract

The aim of this study was to define the structural characteristics in a series of 21 analogues of the anti-histaminergic drug diphenhydramine which are important for the interaction with cytochrome P-450. The compounds gave substrate (type I) binding spectra with rat hepatic microsomal cytochrome P-450. The main findings were: (1) two phenyl rings are needed for strong binding: saturation or elimination of one ring, or restriction of two phenyls with a two-carbon bridge results in a decrease of binding, (2) substitution on one or both aromatic rings has only a small influence on binding, (3) an amine nitrogen contributes to better binding; decrease or absence of basicity weakens binding, and (4) a chain of 4 to 7 atoms connecting the basic centre with the aromatic part is needed; reduction of the chain length, or restriction of it to a cyclic structure causes decrease or loss of binding ability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2750591     DOI: 10.1007/bf02222234

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  11 in total

1.  Active site model of cytochrome P-450 LM2.

Authors:  W Schwarze; J Jaeger; G R Jänig; K Ruckpaul
Journal:  Biochem Biophys Res Commun       Date:  1988-02-15       Impact factor: 3.575

Review 2.  Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents.

Authors:  M Murray
Journal:  Drug Metab Rev       Date:  1987       Impact factor: 4.518

3.  Relation between the structure of benzphetamine analogues and their binding properties to cytochrome P-450 LM2.

Authors:  D R Petzold; H Rein; D Schwarz; M Sommer; K Ruckpaul
Journal:  Biochim Biophys Acta       Date:  1985-06-10

Review 4.  Inhibitors of Cytochrome P-450s and their mechanism of action.

Authors:  B Testa; P Jenner
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

5.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450.

Authors:  T L Poulos; B C Finzel; I C Gunsalus; G C Wagner; J Kraut
Journal:  J Biol Chem       Date:  1985-12-25       Impact factor: 5.157

6.  Defining the active site of cytochrome P-450: the crystal and molecular structure of an inhibitor, SKF-525A.

Authors:  M Rossi; S Markovitz; T Callahan
Journal:  Carcinogenesis       Date:  1987-07       Impact factor: 4.944

7.  Functional group contributions to drug-receptor interactions.

Authors:  P R Andrews; D J Craik; J L Martin
Journal:  J Med Chem       Date:  1984-12       Impact factor: 7.446

8.  Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-N-desmethylorphenadrine (tofenacine) in the rat.

Authors:  A Bast; F A van Kemenade; E M Savenije-Chapel; J Noordhoek
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-06

9.  Cytochrome P-455-nm complex formation in the metabolism of phenylalkylamines. VI. Structure--activity relationships in metabolic intermediary complex formation with a series of alpha-substituted 2-phenylethylamines and corresponding N-hydroxylamines.

Authors:  B Lindeke; U Paulsen-Sörman; G Hallström; A H Khuthier; A K Cho; R C Kammerer
Journal:  Drug Metab Dispos       Date:  1982 Nov-Dec       Impact factor: 3.922

10.  Dual ligand binding of pyridylalkanamides to microsomal cytochrome P-450.

Authors:  C Repond; A Bulgheroni; U A Meyer; J M Mayer; B Testa
Journal:  Biochem Pharmacol       Date:  1986-07-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.